AP
AHL Partners Portfolio holdings
AUM
$6.41B
This Quarter Return
+3.65%
1 Year Return
+23.13%
3 Year Return
+67.91%
5 Year Return
–
10 Year Return
–
AUM
$2.5B
AUM Growth
+$2.5B
(+29%)
Cap. Flow
+$522M
Cap. Flow
% of AUM
20.86%
Top 10 Holdings %
Top 10 Hldgs %
5.5%
Holding
888
New
156
Increased
471
Reduced
151
Closed
109
Top Buys
Top Sells
| 1 |
iShares Core US Aggregate Bond ETF
AGG
|
$24.9M |
| 2 |
Vanguard Real Estate ETF
VNQ
|
$20.5M |
| 3 |
Invesco S&P 500 Low Volatility ETF
SPLV
|
$10.7M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
$6.23M |
| 5 |
Becton Dickinson
BDX
|
$5.17M |
Sector Composition
| 1 | Consumer Discretionary | 20.67% |
| 2 | Healthcare | 18.65% |
| 3 | Technology | 13.38% |
| 4 | Financials | 11.59% |
| 5 | Industrials | 9.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Eli Lilly
LLY
$657B
| $5.56M | 0.22% |
76,468
+36,766
| +93% | +$2.67M |
|
127
Pultegroup
PHM
$26B
| $5.55M | 0.22% |
249,705
+96,589
| +63% | +$2.15M |
|
128
Align Technology
ALGN
$10.3B
| $5.54M | 0.22% |
103,027
+62,839
| +156% | +$3.38M |
|
129
Gilead Sciences
GILD
$140B
| $5.54M | 0.22% |
56,442
+29,811
| +112% | +$2.93M |
|
|
TARO
130
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $5.53M | 0.22% |
39,181
+20,401
| +109% | +$2.88M |
|
131
Aptiv
APTV
$17.3B
| $5.52M | 0.22% |
69,249
+36,229
| +110% | +$2.89M |
|
132
Capri Holdings
CPRI
$2.45B
| $5.52M | 0.22% |
83,948
+66,820
| +390% | +$4.39M |
|
|
HMHC
133
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $5.51M | 0.22% |
234,645
+91,284
| +64% | +$2.14M |
|
134
Waters Corp
WAT
$18B
| $5.5M | 0.22% |
44,251
+21,009
| +90% | +$2.61M |
|
|
ADT
135
DELISTED
ADT CORP
ADT
| $5.5M | 0.22% |
132,471
+81,385
| +159% | +$3.38M |
|
136
Amgen
AMGN
$155B
| $5.5M | 0.22% |
34,392
+18,119
| +111% | +$2.9M |
|
137
IQVIA
IQV
$32.4B
| $5.5M | 0.22% |
82,084
+36,897
| +82% | +$2.47M |
|
138
Bio-Rad Laboratories Class A
BIO
$8.06B
| $5.49M | 0.22% |
40,577
+18,935
| +87% | +$2.56M |
|
139
Quest Diagnostics
DGX
$20.3B
| $5.47M | 0.22% |
71,199
+25,704
| +56% | +$1.98M |
|
140
Harley-Davidson
HOG
$3.54B
| $5.42M | 0.22% |
89,145
+53,431
| +150% | +$3.25M |
|
141
Myriad Genetics
MYGN
$593M
| $5.41M | 0.22% |
152,946
+81,593
| +114% | +$2.89M |
|
142
AbbVie
ABBV
$372B
| $5.37M | 0.21% |
91,749
+51,158
| +126% | +$2.99M |
|
143
Thor Industries
THO
$5.79B
| $5.37M | 0.21% |
84,908
+48,694
| +134% | +$3.08M |
|
144
Andersons Inc
ANDE
$1.4B
| $5.36M | 0.21% |
129,573
+15,226
| +13% | +$630K |
|
|
QGENF
145
DELISTED
QIAGEN NV
QGENF
| $5.36M | 0.21% |
212,557
+102,359
| +93% | +$2.58M |
|
146
Charles River Laboratories
CRL
$8.04B
| $5.35M | 0.21% |
67,516
+25,209
| +60% | +$2M |
|
147
Waste Management
WM
$91.2B
| $5.35M | 0.21% |
98,588
+56,127
| +132% | +$3.04M |
|
148
Bristol-Myers Squibb
BMY
$96B
| $5.34M | 0.21% |
82,829
+37,777
| +84% | +$2.44M |
|
149
Bio-Techne
TECH
$8.5B
| $5.34M | 0.21% |
53,269
+25,683
| +93% | +$2.58M |
|
150
Polaris
PII
$3.18B
| $5.33M | 0.21% |
37,798
+17,412
| +85% | +$2.46M |
|